Senologie - Zeitschrift für Mammadiagnostik und -therapie 2020; 17(02): e45
DOI: 10.1055/s-0040-1710736

Breast cancer biobanking: PATH Biobank contributing to MESI-STRAT

S Torkler
1  PATH Foundation, Biobank, München, Deutschland
C Singrün
1  PATH Foundation, Biobank, München, Deutschland
CA Opitz
2  German Cancer Research Center (DKFZ), Brain Cancer Metabolism Group, Heidelberg, Deutschland
K Thedieck
3  University of Innsbruck, Institute of Biochemistry, Center for Chemistry and Biomedicine (CCB), Innsbruck, Österreich
G Kunz
4  St.-Johannes-Hospital, Clinic for Gynaecology and Obstetrics, Breast Center, Dortmund, Deutschland
T Dimpfl
5  Kassel Hospital, Clinic for Gynaecology and Obstetrics, Interdisciplinary Breast Center (IBZ), Kassel, Deutschland
C Jackisch
6  Sana Hospital, Gynaecology and Obstetrics, Offenbach, Deutschland
T Anzeneder
1  PATH Foundation, Biobank, München, Deutschland
› Author Affiliations

Introduction PATH Foundation operates a biobank under uniform SOPs. Fresh-frozen tissue samples are collected alongside with blood serum and FFPE specimens. Research groups from academia and industry can obtain samples. In 2016 scientists joined forces to form the Horizon2020 funded MESI-STRAT consortium to address unmet needs of women with ER-positive breast cancer. PATH is a co-coordinator within MESI-STRAT.

Material and methods The PATH biobank consists of a centralized database and a decentralized bio repository. The samples are collected and stored in seven institutes for pathology at certified German breast cancer centers. Informed consent (IC) for biobanking and the use of the samples and data for research is obtained from the donors (so far >11,000) individually during pre-operation discussion.

Results In 2016 PATH joined the MESI-STRAT consortium. MESI-STRAT will use systems medicine approaches to explore the interplay of breast cancer metabolism and oncogenic signaling in patients diagnosed with ER-positive disease with theaim to develop marker panels in blood and urine.Such markers shall serve to guide the therapy duration and predict the benefit of a prolonged endocrine therapy (ET). PATH provides already biobanked samples and in addition conducts the MESI-STRAT ET-termination trial. Patients in their last year of ET, who have previously donated samples to PATH, are invited to donate additional blood serum and urine samples.

Conclusion For breast cancer research PATH Biobank is a valuable resource. As shown by different research projects utilizing samples and data provided by PATH and will be further implemented by research efforts like MESI-STRAT.

Publication History

Publication Date:
24 June 2020 (online)

© Georg Thieme Verlag KG
Stuttgart · New York